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ABSTRACT:
1,3-Butadiene (BD) is a multisite carcinogen in rodents, with mice
being much more susceptible than rats. This species difference in
carcinogenicity has been attributed to differences in metabolism.
In this study, coordinated metabolism of butadiene monoxide
(BMO, 5, 25, and 250 mM), the primary reactive metabolite of BD,
was investigated in freshly isolated male B6C3F1 mouse and
Sprague-Dawley rat hepatocytes. The hepatocytes from both spe-
cies catalyzed BMO oxidation to meso- and (6)-diepoxybutane
(DEB), BMO hydrolysis to 3-butene-1,2-diol (BDD), and BMO con-
jugation with glutathione (GSH) to form GSH conjugates (GSBMO).
Metabolite area under the curve (AUC) exhibited dependence on
the BMO concentration and incubation time (0–45 min). However,
the observed BMO activation/detoxication ratios (obtained by di-
viding the AUC for total DEB by the summed AUC values for BDD
and GSBMO) with mouse hepatocytes were approximately 15- to
40-fold higher than the corresponding ratios observed with rat
hepatocytes. At 5 mM BMO, bioactivation in the mouse exceeded
detoxication by approximately 2-fold, whereas at the 250 mM con-
centration, activation was only about 31% of total detoxication. In
rat hepatocytes, the activation-detoxication ratio was relatively
independent of the initial BMO concentration, with flux through the
oxidative pathway at approximately 2 to 5% of the total detoxica-
tion. These results, which are more consistent with in vivo mouse
and rat toxicity data than the metabolic rates obtained with sub-
cellular fractions, illustrate the potential utility of the isolated he-
patocyte model for estimating flux through competing metabolic
pathways and predicting in vivo metabolism of BMO and its parent
compound, BD.
Butadiene (BD2) is a high production commodity chemical used
extensively in the manufacture of synthetic rubber and thermoplastic
resins. In addition, BD is found in cigarette smoke, automobile ex-
haust, and at low concentrations in urban air (Melnick and Kohn,
1995). BD is mutagenic in mammalian and bacterial assays in the
presence of an S-9 activating system (Duverger et al., 1981; Tice et
al., 1987) and is carcinogenic in mice and rats following long-term
inhalation exposure (Owen et al., 1987; Melnick et al., 1990). Epide-
miological evidence suggests a link between occupational exposure to
BD and an increased risk of hematopoietic cancers (Delzell et al.,
1996; Divine and Hartman, 1996). The International Agency for
Research on Cancer (IARC) (1999) has classified BD as a probable
human carcinogen, whereas the United States Department of Health
and Human Services National Toxicology Program (2000) has re-
cently upgraded BD to the classification of “Known to be a Human
Carcinogen”. Mice are significantly more sensitive to the carcinogenic
ac ivity of BD compared with rats, and this difference in susceptibility
is thought to be related in large part to differences in bioactivation of
BD to reactive epoxide metabolites.
Oxidation of BD by cytochrome P450s results in the formation of
butadiene monoxide (BMO; Fig. 1). This reaction has been demon-
strated in microsomes from several rodent and human tissues; the
primary P450s involved in BD oxidation in human liver are CYP2E1
and CYP2A6 (Malvoisin et al., 1979; Csana´dy et al., 1992; Duescher
and Elfarra, 1994). BMO forms covalent adducts with DNA (Citti et
al., 1984; Tretyakova et al., 1997; Selzer and Elfarra, 1999), and it is
directly mutagenic in bacterial and mammalian assays (de Meester et
al., 1978) and carcinogenic in rodents (Van Duuren et al., 1963).
BMO is metabolized by three primary pathways (Fig. 1). First, con-
jugation of BMO with GSH occurs in the presence of cytosolic
glutathioneS-transferases (GSTs) in vitro (Sharer et al., 1991, 1992),
and the resulting conjugates are either excreted into the bile (Sharer
and Elfarra, 1992) or are metabolized further to mercapturic acids,
which are subsequently eliminated in the urine (Elfarra et al., 1995).
The second pathway for BMO metabolism involves P450-mediated
oxidation, resulting in formation of diepoxybutane (DEB). This reac-
tion has been demonstrated in mouse, rat, and human liver micro-
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somes (Seaton et al., 1995; Krause and Elfarra, 1997), and it leads to
formation ofmeso- and (6)-DEB (Krause and Elfarra, 1997). Human
liver microsomal oxidation of BMO to DEB is carried out primarily
by P450 2E1, but P450s 2A6, 2C9, and 3A4 may also contribute to
this pathway, particularly at higher substrate concentrations (Seaton et
al., 1995; Krause and Elfarra, 1997). Because the in vitro mutagenic
potency of DEB is approximately 100-fold greater than BMO (Co-
chrane and Skopek, 1994), DEB is thought to play a critical role in the
carcinogenic activity of BD. The third mechanism for elimination of
BMO is catalyzed by epoxide hydrolases (EH). BMO is hydrolyzed
by microsomal EH in rats, and by both microsomal and soluble forms
in mice and humans (Krause et al., 1997), leading to the formation of
3-butene-1,2-diol (BDD). EH-mediated hydrolysis is believed to be a
major elimination pathway for BMO in rat and human liver (Bechtold
et al., 1994; Krause et al., 1997).
From the preceding discussion, it is apparent that BMO plays a
pivotal role in metabolism and toxicity of BD. BMO undergoes
bioactivation via oxidation to DEB and is detoxified by conjugation
with GSH and by enzymatic hydrolysis. Hence, the carcinogenic
activity of BD is likely to be closely linked to the balance between
activation and detoxication of BMO. Previous in vitro studies of BMO
metabolism have examined bioactivation and detoxication reactions in
isolation (Kreuzer et al., 1991; Csana´dy et al., 1992; Sharer et al.,
1992; Seaton et al., 1995; Boogaard et al., 1996; Krause and Elfarra,
1997; Krause et al., 1997), and the kinetic parameters determined
from these studies have been compared in an attempt to draw con-
clusions concerning the balance of activation and detoxication. Such
studies have yielded useful enzyme kinetic data. However, since
enzyme systems seldom function in isolation, the ability of subcellular
metabolic systems to predict coordinated in vivo metabolism is lim-
ited. The studies described here examine metabolism of BMO in
freshly isolated mouse and rat hepatocytes. Isolated hepatocytes are
ideal for investigating metabolism of compounds that are subject to
multiple parallel and sequential enzymatic pathways because they
allow direct estimation of net exposure of the system to the metabo-
lites of interest. Hepatocytes also retain more of the biological com-
plexity of the whole animal, compared with subcellular fractions (e.g.,
intracellular compartmentalization of enzymes, physiological cofactor
concentrations). The current report compares flux through competing
P450-, GST-, and EH-mediated pathways for BMO metabolism in
isolated rodent hepatocytes at various initial substrate concentrations.
BMO was used as substrate in these studies to facilitate a detailed
investigation of its metabolic fate, since this compound represents a
critical branch point in the carcinogenic action of BD, and the results
obtained may enhance future experimental designs with BD.
Materials and Methods
Chemicals.Trypsin inhibitor (type II-O) was obtained from Sigma Chem-
ical Co. (St. Louis, MO). BMO, (6)-DEB, butane-1,4-diol, reduced GSH and
cyclohexene oxide were obtained from Aldrich Chemical Co. (Milwaukee,
WI). (6)-BDD was obtained from Acros Chemicals (Pittsburgh, PA). Colla-
genase H (fromClostridium histolyticum) was obtained from Boehringer
Mannheim (Indianapolis, IN). Hanks’ balanced salt solution (HBSS) was
obtained from Life Technologies (Gaithersburg, MD).N,O-bis(trimethylsilyl)-
trifluoroacetamide1 10% trimethylchlorosilane (BSTFA1 10% TMCS) was
obtained from Pierce Chemicals (Rockford, IL).S-(2-Hydroxy-3-buten-1-yl-
)glutathione andS-(1-hydroxy-3-butene-2-yl)glutathione, the GSH conjugates
of BMO (GSBMO), were synthesized and purified as described previously
(Sharer et al., 1992). All other chemicals were of reagent grade or higher, and
all solvents were of GC or HPLC grade.
Animals. Male B6C3F1 mice (8–10 weeks old) were obtained from Jack-
son Laboratories (Bar Harbor, ME). Male Sprague-Dawley rats (175–230 g)
were obtained from Charles River Laboratories (Raleigh, NC). Animals were
maintained on a 12-h light/dark cycle and were allowed food and water ad
libitum. Hepatocytes from mice and rats were isolated by two-step EDTA/
collagenase perfusion using a modification of the method described by Ked-
deris and Held (1996). Hepatocytes were prepared at approximately the same
time of day for all experiments to minimize circadian variation in enzyme
levels, GSH, and other cofactors. Briefly, animals were anesthetized deeply
and the liver was perfused via the vena cava for the mice or the portal vein for
the rat first with calcium-free HBSS containing 0.5 mM EDTA followed by 1
mg/ml Collagenase H in HBSS containing 5 mM CaCl2 and 0.27 mg/ml
trypsin inhibitor. Each solution was perfused for approximately 8 min at 5
ml/min for mice and 10 ml/min for the rat. After perfusion, the liver was
carefully excised, placed into a weighing boat filled with Krebs-Henseleit
(KH) buffer supplemented with 0.1% glucose and 0.2% bovine serum albumin,
and gently teased apart with forceps. Dissociated cells were recovered by
centrifugation at 4°C for 2 min at 50g. The pelleted cells were resuspended in
fresh KH buffer and the solution passed through a 292-mm nylon mesh. The
filtrate was centrifuged again at 50g and resuspended in fresh KH buffer. Cell
yield and viability were determined by trypan blue exclusion using a hema-
cytometer. For metabolic experiments, cells were diluted to a concentration of
1.363 106/ml in KH buffer supplemented with 0.1% glucose and 0.2% bovine
serum albumin, and maintained on ice until use.
Metabolic Reactions.Reactions were carried out in 24-ml vials with screw
caps fitted with Teflon-faced septa. Hepatocyte suspension (2.2 ml, 33 106
cells) was placed into vials and purged briefly with 95% O2/5% CO2 before the
vials were sealed. Reactions were carried out at 37°C with gentle shaking (175
rpm). After a 4-min preincubation, the reaction was initiated by addition of 100
ml of BMO solution (in 0.9% NaCl) to give final concentrations of 5, 25, or
250mM in a volume of 2.3 ml. The BMO solution was introduced through the
septum using a gas-tight syringe. At 5-min intervals, reactions were terminated
by immersion in an ice bath. For quantitation ofmeso- and (6)-DEB and BDD,
100 ml of a solution containing 0.5 mM cyclohexene oxide and 0.5 mM
butane-1,4-diol in KH buffer was added after sample cooling on ice (internal
standards for DEB and BDD, respectively). After gentle mixing, a 50-ml
aliquot of cell suspension was removed and cell viability was determined by
trypan blue exclusion. BMO metabolism to GSBMO was examined in separate
experiments carried out exactly as for BMO metabolism to DEB and BDD,
except that the internal standards were omitted.
Sample Preparation.Cell suspensions were transferred to test tubes and
centrifuged at 1500g for 5 min at 4°C to sediment the cells. Recovery
experiments indicated that both DEB and BDD (10–30mM) were rapidly and
uniformly distributed throughout the cell suspension. For this reason, metab-
lites were measured in the reaction medium, which produced an extract that
was free of significant analytical interferences. An aliquot (1.5 ml) of the
FIG. 1. Primary pathways of butadiene monoxide metabolism.
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supernatant was applied to 3-ml capacity Extrelut solid phase extraction
columns (EM Science, Gibbstown, NJ) and allowed to equilibrate for 5 min.
Extraction columns were then eluted with 15 ml of ethyl acetate, and the eluate
was concentrated to a volume of 50ml under a stream of N2 for GC/MS
analysis. For quantitation of GSBMO, 0.5-ml aliquots of cell suspension were
placed in a clean test tube and deproteinated by addition of 0.05 ml of 35%
perchloric acid. After cooling on ice for 10 min, samples were centrifuged at
high speed for 5 min at 4°C to precipitate protein. The supernatant was passed
through 0.2-mm Acrodisc syringe filters (Gelman Sciences, Ann Arbor, MI)
and analyzed by LC/MS in multiple reaction-monitoring mode as described
below.
Quantitation of DEB and BDD by GC/MS. Ethyl acetate extracts were
analyzed by GC/MS using selected ion-monitoring mode. Analyses were
carried out using an HP 6890 Series GC coupled with an HP 6890 Series
mass-selective detector (Hewlett Packard, Palo Alto, CA). Analytes were
separated using a 30-m3 0.32-mm i.d. HP-5 capillary GC column (Hewlett
Packard). The injection port and detector temperatures were 200 and 280°C,
respectively. For analysis ofmeso- and (6)-DEB, the column temperature was
maintained at 60°C for 3 min, then increased to 250°C at a rate of 30°C/min.
The final temperature was maintained for 5 min. The injection volume was 3
ml, and injections were made in splitless mode. For detection of DEB isomers,
ionsm/z 55 (target ion) andm/z 85 (qualifier ion) were monitored (Krause and
Elfarra, 1997). For detection of the internal standard (cyclohexene oxide), ions
m/z 83 (target ion) andm/z 69 (qualifier ion) were monitored. Under these
conditions, the retention times formeso-DEB, (6)-DEB, and cyclohexene
oxide were 3.21, 3.30, and 4.86 min, respectively. Following analysis for DEB
isomers, sample extracts were derivatized with 25ml of BSTFA 1 10% TMCS
for 30 min at 70°C for detection of BDD and butane-1,4-diol (internal stan-
dard) as their bis-trimethylsilyl ethers by GC/MS (Kemper et al., 1998). The
injection port and detector temperatures were the same as for DEB analysis.
The column temperature was maintained at 80°C for 4 min, then increased to
280°C at a rate of 30°C/min. The final temperature was maintained for 3 min.
Detection of BDD was accomplished using ionsm/z 129 (target) andm/z 103
(qualifier), while ionsm/z 116 (target) andm/z 101 (qualifier) were monitored
for butane-1,4-diol (Kemper et al., 1998). Injections (3ml) were carried out in
splitless mode. Under these conditions, BDD and butane-1,4-diol eluted at 4.05
and 5.92 min, respectively. Quantitation of metabolites was achieved by
comparing sample target ion peak area ratios (metabolite/internal standard) to
standard curves prepared from authentic compounds in reaction buffer and
processed exactly as for samples. The limit of detection for both assays was
approximately 0.05 nmol/ml.
Quantitation of GSH Conjugates of BMO by LC/MS/MS. Quantitation
of GSBMO (mixed isomers) was accomplished using a PerkinElmer Sciex API
365 triple quadrupole LC/MS/MS (PerkinElmer Instruments, Norwalk, CT)
coupled to an HPLC. Separation of GSBMO was achieved using a 150-mm
31-mm C18 Hypersil BDS column with 3-mm particle size and 120-Å pore
size (P.J. Colbert, St. Louis, MO). Chromatographic runs were carried out
using 0.05% trifluoroacetic acid in water as solvent A and 95% acetonitrile
containing 0.05% trifluoroacetic acid as solvent B. The column was equili-
brated at 1% B and then increased linearly to 50% B over 25 min. The
percentage of solvent B was then increased to 99% over 10 min, where it was
held for 5 min. The solvent composition was then changed back to the initial
conditions (1% B) over 5 min. Under these conditions, both regioisomers of
GSBMO eluted at 26.4 min. The flow rate was 0.02 ml/min, and the injection
volume was 20ml. For quantitation of GSBMO, the transition ofm/z 378 (M
1 H) to m/z 249 (M 2 glutamate moiety1 H) was monitored with a dwell
time of 0.2 s. The limit of detection for the assay was 0.31 nmol/ml. No
interferences with this reaction were observed in control cell precipitates.
Data Analysis and Statistics.For quantitative comparisons, areas under the
curve (AUC) were calculated for time course data. AUCs were estimated by
the trapezoidal approximation using the AREA transform of the SigmaPlot
software package (SPSS, Chicago, IL). Descriptive statistics were calculated
using the SigmaStat software package (SPSS).
Results
Hepatocyte Viability Under Reaction Conditions. Initial viabil-
ity of hepatocytes isolated by the above procedure was typically 90 to
95%. Preliminary experiments indicated that mouse hepatocytes re-
mained greater than 80% viable for at least 60 min, while rat hepa-
tocytes remained viable for at least 2 h. Furthermore, incubation of
mouse and rat hepatocytes for up to 60 min with BMO, (6)-DEB, or
BDD at concentrations up to 1 mM did not decrease cell viability
compared with control incubations (data not shown). These pilot
experiments, which suggested that BMO and its metabolites were not
acutely cytotoxic at concentrations well above those used or antici-
pated in the current study, are consistent with the results previously
obtained in freshly isolated rat hepatocytes (Nieusma et al., 1997).
Cell viability was assessed by trypan blue exclusion at each time point
in the experiments. The data (not shown) verify that hepatocyte
viability remained greater than 80% throughout the entire experiment.
Oxidation of BMO to meso- and (6)-DEB. The time course of
appearance and disappearance ofmeso-and (6)-DEB in the reaction
medium following incubation of BMO with mouse and rat hepato-
cytes is illustrated in Fig. 2. The data from these experiments were
used to calculate areas under the concentration versus time curve
FIG. 2. Oxidation of BMO to meso- and (6)-diepoxybutane in mouse (A) and rat
(B) hepatocytes.
BMO (5, 25, or 250mM) was incubated with hepatocytes (33 106/vial) for the
indicated times. Incubation conditions and analytical procedures are described under
Materials and Methods. Values are means6 S.D. for three individual hepatocyte
preparations.F, 5mM BMO, meso-DEB; E, 5 mM BMO, (6)-DEB; Œ, 25 mM
BMO, meso-DEB; ‚, 25 mM BMO, (6)-DEB; f, 250mM BMO, meso-DEB; and
M, 250 mM BMO, (6)-DEB.
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(AUC0–45 min), which are presented in Table 1. The AUC provides an
index of overall exposure of the cell system to the metabolites of
interest. In mouse hepatocytes (Fig. 2A), detectable formation of both
meso- and (6)-DEB occurred at all BMO concentrations tested. At the
low and middle BMO concentrations (5 and 25mM), peak levels of
the DEB isomers occurred within 10 to 15 min of the addition of
substrate and declined thereafter. At 250mM BMO, the concentration
of (6)- and meso-DEB reached an apparent plateau after approxi-
mately 30 min. At all substrate concentrations tested, the levels of
(6)-DEB were significantly higher thanmeso-DEB. However, anal-
ysis of the AUC data for the DEB isomers and total DEB (Table 1)
indicates that the relative amounts of (6)- andmeso-DEB varied with
initial BMO concentration. As the BMO concentration was increased,
the fractional contribution ofmeso-DEB increased from 13.8 to 54.8%
of total DEB.
Flux of BMO through the diepoxide pathway in rat hepatocytes is
shown in Fig. 2B. Concentrations ofmeso- and (6)-DEB measured in
rat hepatocytes following exposure to BMO were quite low compared
with the results obtained with mouse cells. Indeed, nomeso-DEB was
detected in rat hepatocytes exposed to 5mM BMO, whereas this
isomer was detectable for at least 20 min at this BMO concentration
in mouse hepatocytes. Peak concentrations of DEB in rat hepatocytes
generally occurred within 10 min, with the exception of (6)-DEB
after the 250mM BMO exposure, in which case the peak concentra-
tion was reached at approximately 20 min. In contrast to mice, DEB
had disappeared completely by the end of the experiment, except for
(6)-DEB at the highest BMO concentration, which had declined to
approximately half of its peak value by the end of the experiment. As
with mouse hepatocytes, the fractional contribution ofmeso-DEB to
total DEB increased with increasing BMO concentration (Table 1).
However, the effect was less pronounced in rat hepatocytes, with a
maximum fractional contribution of approximately 17% at the highest
BMO exposure concentration. Overall, total exposure of rat hepato-
cytes to DEB was markedly lower than in mouse cells exposed to the
same concentration of BMO. For example, the AUC0–45 for total
DEB in rat cells ranged from 7.8 to 12.9% of the value in mouse
hepatocytes over the BMO concentration range examined (Table 1).
Hydrolysis of BMO to BDD. The time course of hydrolysis of
BMO to BDD in mouse and rat hepatocytes is shown in Fig. 3, and the
AUCs calculated from these data are presented in Table 1. In mouse
hepatocytes (Fig. 3A), peak concentrations of BDD occurred at 10,
15, and 40 min following exposure to 5, 25, and 250mM BMO,
respectively. At the low and middle BMO concentrations, the BDD
concentration decreased in the latter part of the experiment, while at
the highest BMO concentration, BDD reached an apparent plateau
after 35 to 40 min. Elimination of BDD appears to occur relatively
slowly compared with elimination ofmeso- and (6)-DEB. A similar
pattern of BDD formation was observed in rat hepatocytes exposed to
increasing concentrations of BMO (Fig. 3B). As with mouse hepato-
cytes, the time to peak concentration of BDD in rat hepatocytes varied
with the BMO concentration, and elimination of the diol appeared to
be quite slow. However, peak concentrations of BDD measured in rat
hepatocyte suspensions were approximately 3- to 6-fold higher than in
the corresponding mouse experiments. Species differences in flux
through the hydrolysis pathway are most clearly seen by comparison
TABLE 1
AUC for BMO metabolites in mouse and rat hepatocytes exposed to BMO.
AUCs were calculated from time course experiments as described underMat ials and Methods.
Species BMO
AUC0–45 min(nmol z min/10
6 cells)
meso-DEB (6)-DEB Total DEB BDD GSBMO DEB/(BDD1 GSBMO)
mM
Mouse 5 8.76 4.1a 54.46 19.2 63.16 23.2 9.26 1.0 22.06 14.2 2.02
25 43.96 13.1 153.36 17.2 197.26 27.7 132.96 24.0 117.26 32.2 0.79
250 218.26 28.8 398.06 24.4 616.26 52.8 908.06 171.7 1101.36 321.8 0.31
Rat 5 N.D. 4.96 0.8 4.96 0.8 77.96 20.0 26.66 1.0 0.05
25 0.96 0.9 11.66 2.5 12.56 3.4 435.16 97.8 152.66 9.4 0.02
250 13.46 0.5 66.36 3.3 79.76 2.7 3402.56 754.8 1552.16 205.7 0.02
N.D., not detected.
a Values are means6 S.D. for three individual hepatocyte preparations.
FIG. 3. Hydrolysis of BMO to 3-butene-1,2-diol in mouse (A) and rat (B)
hepatocytes.
BMO (5, 25, or 250mM) was incubated with hepatocytes (33 106/vial) for the
indicated times. Incubation conditions and analytical procedures are described under
Materials and Methods. Values are means6 S.D. for three individual hepatocyte
preparations.
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of the AUC data for this metabolite (Table 1). The AUC for BDD was
approximately 3- to 7-fold greater in rat hepatocytes compared with
mouse hepatocytes. For both peak concentration and AUC, the great-
est differences were found following the 5mM BMO exposure.
Conjugation of BMO with GSH. Formation of GSH conjugates of
BMO (GSBMO, combined regioisomers) by mouse and rat hepato-
cytes is illustrated in Fig. 4. In mouse (Fig. 4A), conjugation with
GSH occurred very rapidly, with significant levels of GSBMO found
even in samples quenched immediately after addition of substrate.
Peak levels were reached within 5 min and appeared to decline
slightly with time thereafter. However, because of the high variability
of these measurements, the apparent decline may be an artifact. In rat
hepatocytes (Fig. 4B), GSBMO formation appears to proceed more
slowly, with peak levels occurring after 10 to 20 min, depending on
the BMO concentration. Similar peak concentrations of conjugates
were observed in rats compared with mice, but the apparent decline in
conjugate concentration with time seen in mouse hepatocytes was not
evident in rats. Comparison of AUC values for GSBMO formation
(Table 1) suggests that similar amounts of BMO were metabolized via
this pathway in both species. For both mice and rats, there was an
approximately linear increase in AUC for GSBMO with increasing
initial BMO concentration.
Discussion
Isolated mouse and rat hepatocytes catalyzed oxidation of BMO to
DEB. Once formed, DEB may be eliminated via hydrolysis to epoxy-
butanediol and erythritol and by GSH conjugation, catalyzed by
GSTs. The former reaction was observed in rat and human liver
microsomes (Krause and Elfarra, 1997), while the latter reaction was
demonstrated in cytosolic preparations from mouse and rat tissues
(Boogaard et al., 1996; Nieusma et al., 1998). While bothmeso-and
(6)-DEB were detected in the mouse and rat hepatocytes, (6)-DEB
was preferentially detected overmeso-DEB at the three BMO con-
centrations used, althoughmeso-DEB detection increased at high
BMO concentrations (Table 1; Fig. 2). These results are consistent
with our previous results showing a similar concentration dependence
in the stereoselectivity of DEB detected from BMO in mouse and rat
liver microsomes (Krause and Elfarra, 1997). In that study,meso-DEB
was found to be hydrolyzed more efficiently by rat liver microsomal
EH compared with (6)-DEB (Krause and Elfarra, 1997), whereas
mouse liver microsomes displayed little hydrolytic activity toward
both DEB isomers. Collectively, these findings are consistent with the
rapid and relatively complete elimination of DEB from rat hepato-
cytes compared with mouse hepatocytes (Fig. 2).
DEB can also be conjugated with GSH, both enzymatically, and to
a lesser extent by direct reaction (Boogaard et al., 1996; Nieusma et
al., 1998). In liver cytosol from rats and mice, conjugation is appar-
ently followed by rapid hydration of the remaining epoxide moiety,
leading to formation of trihydroxybutylglutathione conjugates (Boo-
gaard et al., 1996). Because species comparisons demonstrated little
difference in DEB-GSH conjugation kinetics between cytosolic prep-
arations from mice and rats (Boogaard et al., 1996), formation of GSH
conjugates probably contributes little to species differences in DEB
levels detected in hepatocytes incubated with BMO. Rather, the major
determinants of mouse and rat differences in DEB exposure in BMO-
treated hepatocytes are likely to be rates of BMO oxidation and DEB
hydrolysis. Overall, the hepatocyte data suggest that at equivalent
BMO doses, DEB exposure in rats in vivo will be significantly lower
than in mice.
Mouse and rat hepatocytes readily hydrolyzed BMO to BDD (Fig.
3). Small amounts of BDD were detected in the urine of animals
exposed to BD (Nauhaus et al., 1996; Anttinen-Klemetti et al., 1999)
and BMO (Krause et al., 1997). Enzymatic hydrolysis of BMO has
been demonstrated directly (Krause et al., 1997) and indirectly (Kreu-
zer et al., 1991; Csana´dy et al., 1992) in liver microsomal and
cytosolic preparations from mice and rats. BMO microsomal hydro-
lysis is approximately 3-fold more efficient in rat liver microsomes
compared with mouse liver microsomes (Krause et al., 1997). No
cytosolic EH activity toward BMO was observed in rat liver, whereas
the mouse microsomal and cytosolic BMO EH activities were com-
parable under saturating substrate concentrations (Krause et al., 1997).
These results suggest the cytosolic form of EH may contribute sig-
nificantly to BMO hydrolysis in mouse hepatocytes. Relatively slow
elimination of BDD from both rat and mouse hepatocytes was ob-
s rved in the current study (Fig. 3). In vitro, BDD is metabolized by
cytosolic alcohol dehydrogenases (Kemper and Elfarra, 1996) and by
cytochrome P450s (Sabourin et al., 1992). Dehydrogenation of BDD,
presumably to 2-hydroxy-3-butenal, is a low-affinity, high-capacity
pathway in mouse and rat liver cytosol (Kemper and Elfarra, 1996);
the efficiency of this in vitro reaction was similar in the two species
(Vmax/Km > 0.53–0.66). NADPH-dependent oxidation of BDD by
mouse and rat liver microsomes led to formation of hydroxymethyl-
vinyl ketone (Kemper et al., 1997). This compound is thought to be
the precursor to 1,2-dihydroxy-4-(N-acetylcysteinyl)butane, the pri-
FIG. 4. Conjugation of BMO with glutathione in mouse (A) and rat (B)
hepatocytes.
BMO (5, 25, or 250mM) was incubated with hepatocytes (33 106/vial) for the
indicated times. Incubation conditions and analytical procedures are described under
Materials and Methods. Values are means6 S.D. for three individual hepatocyte
preparations.
834 KEMPER ET AL.
mary urinary metabolite detected in monkeys and humans exposed to
BD (Sabourin et al., 1992; Bechtold et al., 1994).
Another major pathway for BMO metabolism is conjugation with
GSH, catalyzed by cytosolic GSTs, resulting in the formation of
regioisomers of GSBMO. Previous studies have demonstrated forma-
tion of both regioisomers of GSBMO both in vitro (Sharer et al., 1991,
1992; Csana´dy et al., 1992) and in vivo (Sabourin et al., 1992; Sharer
and Elfarra, 1992; Bechtold et al., 1994; Elfarra et al., 1995), but the
HPLC detection methods used in these studies were not sensitive
enough to quantitate the GSH conjugates of BMO in isolated hepa-
tocytes. Both regioisomers of GSBMO were detected by our LC/MS
methodology, although we were unable to resolve these regioisomers
to permit their individual quantitation. The results indicate that similar
amounts of BMO were metabolized by GSH conjugation in mouse
and rat hepatocytes. This is consistent with previous studies from our
laboratory, which showed that mice and rats dosed with BMO (20
mg/kg, i.p.) excreted similar amounts of combinedS-(2-hydroxy-3-
buten-1-yl)-N-acetyl-L-cysteine and S-(1-hydroxy-3-buten-2-yl)-N-
acetyl-L-cysteine in the urine within 24 h (Elfarra et al., 1995).
Likewise, in vitro kinetic experiments using mouse and rat liver
cytosol revealed similar maximal formation rates andVmax/Km ratios
from these species (Csana´dy et al., 1992; Sharer et al., 1992). Thus,
conjugation of BMO with GSH does not appear to be a major
determinant of differences in BMO toxicity in mice and rats.
In the current studies, the AUCs for metabolite time courses were
used as an index of overall exposure of the cell to each metabolite and
as a measure of flux of BMO through each of its major metabolic
pathways. Since recovery experiments indicated that DEB and BDD
(10–30mM) were rapidly and uniformly distributed throughout the
hepatocyte suspension, these metabolites were measured in the reac-
tion medium instead of the intact or homogenized suspension. Be-
cause the distribution of metabolites at lower concentrations within
the system was not determined, it is possible that at early time points
in the experiments, intracellular metabolites may not have fully equil-
ibrated with the extracellular medium, resulting in underestimation of
AUCs. Nevertheless, since concentrations of metabolites measured in
the medium primarily represent concentrations in the whole suspen-
sions averaged over the course of the experiment, and since any
underestimation at early time points would be similar in both species
tested, the results of our comparative analysis are still valid. While
separate experiments were carried out to quantitate GSBMO forma-
tion, the metabolic system could easily be scaled up such that all three
metabolites could be measured in the same cell suspension.
The observed species differences in the AUCs in our studies reflect
species differences in both metabolism and toxicity of mice and rats
exposed to BD (Owen et al., 1987; Melnick et al., 1990; Himmelstein
et al., 1995; Himmelstein et al., 1997; Thorton-Manning et al., 1997).
Activation-detoxication ratios for BMO may be calculated by dividing
the AUC for total DEB by the summed AUC values for GSBMO and
BDD at each concentration (Table 1). In mouse hepatocytes, there is
an inverse relationship between exposure concentration and activa-
tion-detoxication ratio. At the lowest concentration, bioactivation of
BMO exceeds detoxication capacity by approximately 2-fold, whereas
at the highest concentration, activation is only about 31% of total
detoxication. In rat hepatocytes, the activation-detoxication ratio is
relatively independent of the initial BMO concentration, with flux
through the oxidative pathway at approximately 2 to 5% of total
detoxication. Thus, depending on the exposure concentration, the
activation-detoxication ratio for BMO in mouse hepatocytes was
between 15- and 40-fold higher than in rat hepatocytes. These results,
which are consistent with the reported 40-fold higher blood levels of
DEB in mice exposed to BD (62 ppm) in comparison with the rat
blood levels (Himmelstein et al., 1997; Thorton-Manning et al., 1997),
suggest that even in the absence of rate-limiting formation of BMO
from BD, mice would be more sensitive to the carcinogenic effects of
BMO compared with rats, particularly at lower BMO concentrations.
Because mouse liver microsomes are also more effective in BD
oxidation to BMO in comparison with rat liver microsomes (Csana´dy
et al., 1992; Duescher and Elfarra, 1994), freshly isolated hepatocytes
would probably exhibit even greater species differences in bioactiva-
ion of BD to DEB than that observed with BMO in the present study.
Studies using hepatocytes complement subcellular metabolism
studies by providing a significant increase in biological complexity
while still allowing the high degree of control characteristic of simpler
in vitro systems. In the present study, rodent hepatocytes catalyzed
formation and elimination of all three of the major biotransformations
f BMO characterized in subcellular kinetic studies: oxidation to
meso- and (6)-DEB, hydrolysis to BDD, and conjugation with GSH.
These results, which reflect in vivo metabolic handling of BMO
(Himmelstein et al., 1995, 1997; Thorton-Manning et al., 1997), are
more consistent with mouse and rat in vivo toxicity data than the in
vitro kinetic studies in rodent subcellular fractions (Kreuzer et al.,
1991; Sharer et al., 1992; Seaton et al., 1995; Boogaard et al., 1996;
Krause and Elfarra, 1997; Krause et al., 1997). Hence, intact cells are
useful for bridging the gap between subcellular and whole animal
systems and may provide a more realistic picture of overall in vivo
metabolism. Prolonged inhalation exposure of mice to BD (625 and
1250 ppm) has been associated with blood BMO concentrations of 4
to 8 mM, respectively (Himmelstein et al., 1995, 1997), which are
comparable with the low BMO concentration used in the current
study.
The isolated hepatocyte approach combined with sensitive analyt-
ical methods allows a great deal of information to be extracted from
a few experiments. Although the current studies focused on primary
metabolites of BMO, this approach could be used to examine produc-
tion of secondary and tertiary metabolites, such as epoxybutanediol
and hydroxymethylvinyl ketone, and to study formation of covalent
adducts with nucleophilic targets in cellular macromolecules. These
experiments, however, require the development of highly sensitive
alytical methods appropriate for use in the isolated cell model. The
consistency between our results and the carcinogenic susceptibility of
mice and rats to BD suggests that isolated hepatocytes may be a useful
model for predicting human susceptibility to BD and its metabolites.
The increasing commercial availability of cryopreserved human hepa-
tocytes should allow further development of this model and its appli-
ca ion to human risk assessment. Clearly, further studies are needed to
realize the full potential of isolated hepatocyte models for investiga-
tion of the role of metabolism in species differences in metabolism
and toxicity of BD and related compounds.
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